Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG

Publication Date:
2018-11-02
Publisher:
The Society of Nuclear Medicine (SNM)
Print ISSN:
0022-3123
Topics:
Medicine
Published by:
http://www.snm.org/
_version_ 1836399078767853568
autor Kane, A., Thorpe, M. P., Morse, M. A., Howard, B. A., Oldan, J. D., Zhu, J., Wong, T. Z., Petry, N. A., Reiman, R., Borges-Neto, S.
beschreibung This retrospective analysis identifies predictors of survival in a cohort of patients with meta-iodobenzylguanidine (MIBG)–positive stage IV pulmonary and gastroenteropancreatic neuroendocrine tumor (P/GEP-NET) treated with 131 I-MIBG therapy, to inform treatment selection and posttreatment monitoring. Methods: Survival, symptoms, imaging, and biochemical response were extracted via chart review from 211 P/GEP-NET patients treated with 131 I-MIBG between 1991 and 2014. For patients with CT follow-up ( n = 125), imaging response was assessed by RECIST 1.1 if images were available ( n = 76) or by chart review of the radiology report if images could not be reviewed ( n = 49). Kaplan–Meier analysis and Cox multivariate regression estimated survival and progression-free survival benefits predicted by initial imaging, biochemical response, and symptomatic response. Results: All patients had stage IV disease at the time of treatment. Median survival was 29 mo from the time of treatment. Symptomatic response was seen in 71% of patients, with the median duration of symptomatic relief being 12 mo. Symptomatic response at the first follow-up predicted a survival benefit of 30 mo ( P 〈 0.001). Biochemical response at the first clinical follow-up was seen in 34% of patients, with stability of laboratory values in 48%; response/stability versus progression extended survival by 40 mo ( P 〈 0.03). Imaging response (20% of patients) or stability (60%) at the initial 3-mo follow-up imaging extended survival by 32 mo ( P 〈 0.001). Additionally, multiple 131 I-MIBG treatments were associated with 24 mo of additional survival ( P 〈 0.05). Conclusion: Therapeutic 131 I-MIBG for metastatic P/GEP-NETs appears to be an effective means of symptom palliation. Imaging, biochemical, and symptomatic follow-up help prognosticate expected survival after 131 I-MIBG therapy. Multiple rounds of 131 I-MIBG are associated with prolonged survival.
citation_standardnr 6351777
datenlieferant ipn_articles
feed_id 9585
feed_publisher The Society of Nuclear Medicine (SNM)
feed_publisher_url http://www.snm.org/
insertion_date 2018-11-02
journalissn 0022-3123
publikationsjahr_anzeige 2018
publikationsjahr_facette 2018
publikationsjahr_intervall 7984:2015-2019
publikationsjahr_sort 2018
publisher The Society of Nuclear Medicine (SNM)
quelle Journal of Nuclear Medicine
relation http://jnm.snmjournals.org/cgi/content/short/59/11/1708?rss=1
search_space articles
shingle_author_1 Kane, A., Thorpe, M. P., Morse, M. A., Howard, B. A., Oldan, J. D., Zhu, J., Wong, T. Z., Petry, N. A., Reiman, R., Borges-Neto, S.
shingle_author_2 Kane, A., Thorpe, M. P., Morse, M. A., Howard, B. A., Oldan, J. D., Zhu, J., Wong, T. Z., Petry, N. A., Reiman, R., Borges-Neto, S.
shingle_author_3 Kane, A., Thorpe, M. P., Morse, M. A., Howard, B. A., Oldan, J. D., Zhu, J., Wong, T. Z., Petry, N. A., Reiman, R., Borges-Neto, S.
shingle_author_4 Kane, A., Thorpe, M. P., Morse, M. A., Howard, B. A., Oldan, J. D., Zhu, J., Wong, T. Z., Petry, N. A., Reiman, R., Borges-Neto, S.
shingle_catch_all_1 Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG
This retrospective analysis identifies predictors of survival in a cohort of patients with meta-iodobenzylguanidine (MIBG)–positive stage IV pulmonary and gastroenteropancreatic neuroendocrine tumor (P/GEP-NET) treated with 131 I-MIBG therapy, to inform treatment selection and posttreatment monitoring. Methods: Survival, symptoms, imaging, and biochemical response were extracted via chart review from 211 P/GEP-NET patients treated with 131 I-MIBG between 1991 and 2014. For patients with CT follow-up ( n = 125), imaging response was assessed by RECIST 1.1 if images were available ( n = 76) or by chart review of the radiology report if images could not be reviewed ( n = 49). Kaplan–Meier analysis and Cox multivariate regression estimated survival and progression-free survival benefits predicted by initial imaging, biochemical response, and symptomatic response. Results: All patients had stage IV disease at the time of treatment. Median survival was 29 mo from the time of treatment. Symptomatic response was seen in 71% of patients, with the median duration of symptomatic relief being 12 mo. Symptomatic response at the first follow-up predicted a survival benefit of 30 mo ( P < 0.001). Biochemical response at the first clinical follow-up was seen in 34% of patients, with stability of laboratory values in 48%; response/stability versus progression extended survival by 40 mo ( P < 0.03). Imaging response (20% of patients) or stability (60%) at the initial 3-mo follow-up imaging extended survival by 32 mo ( P < 0.001). Additionally, multiple 131 I-MIBG treatments were associated with 24 mo of additional survival ( P < 0.05). Conclusion: Therapeutic 131 I-MIBG for metastatic P/GEP-NETs appears to be an effective means of symptom palliation. Imaging, biochemical, and symptomatic follow-up help prognosticate expected survival after 131 I-MIBG therapy. Multiple rounds of 131 I-MIBG are associated with prolonged survival.
Kane, A., Thorpe, M. P., Morse, M. A., Howard, B. A., Oldan, J. D., Zhu, J., Wong, T. Z., Petry, N. A., Reiman, R., Borges-Neto, S.
The Society of Nuclear Medicine (SNM)
0022-3123
00223123
shingle_catch_all_2 Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG
This retrospective analysis identifies predictors of survival in a cohort of patients with meta-iodobenzylguanidine (MIBG)–positive stage IV pulmonary and gastroenteropancreatic neuroendocrine tumor (P/GEP-NET) treated with 131 I-MIBG therapy, to inform treatment selection and posttreatment monitoring. Methods: Survival, symptoms, imaging, and biochemical response were extracted via chart review from 211 P/GEP-NET patients treated with 131 I-MIBG between 1991 and 2014. For patients with CT follow-up ( n = 125), imaging response was assessed by RECIST 1.1 if images were available ( n = 76) or by chart review of the radiology report if images could not be reviewed ( n = 49). Kaplan–Meier analysis and Cox multivariate regression estimated survival and progression-free survival benefits predicted by initial imaging, biochemical response, and symptomatic response. Results: All patients had stage IV disease at the time of treatment. Median survival was 29 mo from the time of treatment. Symptomatic response was seen in 71% of patients, with the median duration of symptomatic relief being 12 mo. Symptomatic response at the first follow-up predicted a survival benefit of 30 mo ( P < 0.001). Biochemical response at the first clinical follow-up was seen in 34% of patients, with stability of laboratory values in 48%; response/stability versus progression extended survival by 40 mo ( P < 0.03). Imaging response (20% of patients) or stability (60%) at the initial 3-mo follow-up imaging extended survival by 32 mo ( P < 0.001). Additionally, multiple 131 I-MIBG treatments were associated with 24 mo of additional survival ( P < 0.05). Conclusion: Therapeutic 131 I-MIBG for metastatic P/GEP-NETs appears to be an effective means of symptom palliation. Imaging, biochemical, and symptomatic follow-up help prognosticate expected survival after 131 I-MIBG therapy. Multiple rounds of 131 I-MIBG are associated with prolonged survival.
Kane, A., Thorpe, M. P., Morse, M. A., Howard, B. A., Oldan, J. D., Zhu, J., Wong, T. Z., Petry, N. A., Reiman, R., Borges-Neto, S.
The Society of Nuclear Medicine (SNM)
0022-3123
00223123
shingle_catch_all_3 Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG
This retrospective analysis identifies predictors of survival in a cohort of patients with meta-iodobenzylguanidine (MIBG)–positive stage IV pulmonary and gastroenteropancreatic neuroendocrine tumor (P/GEP-NET) treated with 131 I-MIBG therapy, to inform treatment selection and posttreatment monitoring. Methods: Survival, symptoms, imaging, and biochemical response were extracted via chart review from 211 P/GEP-NET patients treated with 131 I-MIBG between 1991 and 2014. For patients with CT follow-up ( n = 125), imaging response was assessed by RECIST 1.1 if images were available ( n = 76) or by chart review of the radiology report if images could not be reviewed ( n = 49). Kaplan–Meier analysis and Cox multivariate regression estimated survival and progression-free survival benefits predicted by initial imaging, biochemical response, and symptomatic response. Results: All patients had stage IV disease at the time of treatment. Median survival was 29 mo from the time of treatment. Symptomatic response was seen in 71% of patients, with the median duration of symptomatic relief being 12 mo. Symptomatic response at the first follow-up predicted a survival benefit of 30 mo ( P < 0.001). Biochemical response at the first clinical follow-up was seen in 34% of patients, with stability of laboratory values in 48%; response/stability versus progression extended survival by 40 mo ( P < 0.03). Imaging response (20% of patients) or stability (60%) at the initial 3-mo follow-up imaging extended survival by 32 mo ( P < 0.001). Additionally, multiple 131 I-MIBG treatments were associated with 24 mo of additional survival ( P < 0.05). Conclusion: Therapeutic 131 I-MIBG for metastatic P/GEP-NETs appears to be an effective means of symptom palliation. Imaging, biochemical, and symptomatic follow-up help prognosticate expected survival after 131 I-MIBG therapy. Multiple rounds of 131 I-MIBG are associated with prolonged survival.
Kane, A., Thorpe, M. P., Morse, M. A., Howard, B. A., Oldan, J. D., Zhu, J., Wong, T. Z., Petry, N. A., Reiman, R., Borges-Neto, S.
The Society of Nuclear Medicine (SNM)
0022-3123
00223123
shingle_catch_all_4 Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG
This retrospective analysis identifies predictors of survival in a cohort of patients with meta-iodobenzylguanidine (MIBG)–positive stage IV pulmonary and gastroenteropancreatic neuroendocrine tumor (P/GEP-NET) treated with 131 I-MIBG therapy, to inform treatment selection and posttreatment monitoring. Methods: Survival, symptoms, imaging, and biochemical response were extracted via chart review from 211 P/GEP-NET patients treated with 131 I-MIBG between 1991 and 2014. For patients with CT follow-up ( n = 125), imaging response was assessed by RECIST 1.1 if images were available ( n = 76) or by chart review of the radiology report if images could not be reviewed ( n = 49). Kaplan–Meier analysis and Cox multivariate regression estimated survival and progression-free survival benefits predicted by initial imaging, biochemical response, and symptomatic response. Results: All patients had stage IV disease at the time of treatment. Median survival was 29 mo from the time of treatment. Symptomatic response was seen in 71% of patients, with the median duration of symptomatic relief being 12 mo. Symptomatic response at the first follow-up predicted a survival benefit of 30 mo ( P < 0.001). Biochemical response at the first clinical follow-up was seen in 34% of patients, with stability of laboratory values in 48%; response/stability versus progression extended survival by 40 mo ( P < 0.03). Imaging response (20% of patients) or stability (60%) at the initial 3-mo follow-up imaging extended survival by 32 mo ( P < 0.001). Additionally, multiple 131 I-MIBG treatments were associated with 24 mo of additional survival ( P < 0.05). Conclusion: Therapeutic 131 I-MIBG for metastatic P/GEP-NETs appears to be an effective means of symptom palliation. Imaging, biochemical, and symptomatic follow-up help prognosticate expected survival after 131 I-MIBG therapy. Multiple rounds of 131 I-MIBG are associated with prolonged survival.
Kane, A., Thorpe, M. P., Morse, M. A., Howard, B. A., Oldan, J. D., Zhu, J., Wong, T. Z., Petry, N. A., Reiman, R., Borges-Neto, S.
The Society of Nuclear Medicine (SNM)
0022-3123
00223123
shingle_title_1 Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG
shingle_title_2 Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG
shingle_title_3 Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG
shingle_title_4 Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG
timestamp 2025-06-30T23:37:16.030Z
titel Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG
titel_suche Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG
topic WW-YZ
uid ipn_articles_6351777